

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/656,781
Filing Date	09-05-03
First Named Inventor	Betz, <i>et al.</i>
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	B185 1230.1 (MSC 8016)


Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	6/24/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 27 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. *If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



PTO/SB/O8B (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/656,781
				Filing Date	09-05-03
				First Named Inventor	Betz, et al.
				Art Unit	1614
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	B185 1230.1 (MSC 8016)


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T ²
AD ↓	D1	Bogges, K.A., et al., "Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy," <i>Am. J. Obstet. Gynecol.</i> , 176(2): 443-451 (1997).	
	D2	Corbino, N., et al., "The role of anti-herpes specific serum IgA levels as a marker in cervical oncogenesis," <i>Eur. J. Gynaec. Oncol.</i> , 10(2): 103-108 (1989).	
	D3	Habeeb, A.F.S.A., and R.D. Francis, "Preparation of human immunoglobulin free of plasmin and anticomplement activities," <i>Vox Sang.</i> 32(3): 143-158 (1977).	
	D4	Leibl, H., et al., Method for the isolation of biologically active monomeric immunoglobulin A from a plasma fraction," <i>Journal of Chromatography B.</i> , 678(2): 173-180 (1996).	
	D5	European Patent Office Partial International Search Report (PCT/US2004/028559, dated 09 December 2004).	


Examiner Signature		Date Considered	6/2/05
--------------------	--	-----------------	--------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DKT NO. B185 1230.1		SERIAL NO. 10/656,781			
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT						APPLICANT Betz, <i>et al.</i>	
						FILING DATE 09/05/2003		GROUP 1614	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.
<i>AS</i> ↓	P1	5,505,945	04/09/96	Gristina, <i>et al.</i>	424	164.1	
	P2	5,530,102	06/25/96	Gristina, <i>et al.</i>	530	391.1	
	P3	5,681,565	10/28/97	Gristina, <i>et al.</i>	424	164.1	
	P4	5,707,627	01/13/98	Gristina, <i>et al.</i>	424	164.1	
	P5	5,718,899	02/17/98	Gristina, <i>et al.</i>	424	164.1	
	P6	5,817,312	10/06/98	Gristina, <i>et al.</i>	424	164.1	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL	TRANSLATION YES NO
OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)							
EXAMINER					DATE CONSIDERED		
					6/2/05		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DKT NO.
B185 1230.1

SERIAL NO.
10/656,781

APPLICANT
Ulrich Betz, *et al.*

FILING DATE
09/05/03

GROUP
1614

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.
	P1	U.S. Pat. No. 6,307,028 B1	10/23/01	Lebing, <i>et al.</i>	530	390.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)

75	D1	Elrich, K.S., <i>et al.</i> , "Prevention and Treatment of Experimental Herpes Simplex Virus Encephalitis with Human Immune Serum Globulin," <i>Antimicrobial Agents and Chemotherapy</i> , 31(7): 1006-1009 (1987).
	D2	Epstein, S.P., <i>et al.</i> , "Efficacy of Polyclonal Antibodies for Treatment of Ocular Herpes Simplex Infection," <i>Cornea</i> , 20(5): 495-500 (2001).
	D3	LeBlanc, R.A., <i>et al.</i> , "Treatment of HSV-1 Infection with Immunoglobulin or Acyclovir: Comparison of Their Effects on Viral Spread, Latency, and Reactivation," <i>Virology</i> , 262(1): 230-236 (1999).
	D4	Raizman, M.B. and C.S. Foster, "Passive transfer of anti-HSV-1 IgG protects against stromal keratitis in mice," <i>Current Eye Research</i> , 7(8): 823-829 (1988).
	D5	Ritchie, M.H., <i>et al.</i> , "Passive Transfer of Anti-Herpes Simplex Virus Type 2 Monoclonal and Polyclonal Antibodies Protect Against Herpes Simplex Virus Type 1-Induced but Not Herpes Simplex Virus Type 2-Induced Stromal Keratitis," <i>Investigative Ophthalmology & Visual Science</i> , 34(8): 2460-2468 (1993).

EXAMINER

DATE CONSIDERED

6/2/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.